TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04265378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study: NCT00149630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
Study: NCT04032548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study: NCT00149630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Lactose was added to both the active disulfiram and placebo doses so they tasted identical.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactose
Description: Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
Study: NCT01174329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic neuro-electrostimulation by Saliwell Crown
Description: Continuous stimulation of the lingual nerve by Saliwell Crown

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-regulated neuro-electrostimulation by Saliwell Crown
Description: On-demand stimulation of the lingual nerveby Saliwell Crown
Study: NCT01175707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT02455687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hi-dose iv MgSO4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hi-dose iv MgSO4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized budesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Std-dose iv MgSO4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Std-dose iv MgSO4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline
Study: NCT03223883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplement for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for 12 months
Study: NCT03357640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined oral contraceptive pills
Description: one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: combined oral contraceptive pills
Description: one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
Study: NCT04137874

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: eSTROKE model
Description: The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional prehospital care
Study: NCT04238637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous Infusion)
Study: NCT02256332

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose plant based ingredient
Description: Reference food with high dose of plant based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reference food format
Description: Reference food without plant-based ingredient
Study: NCT01326052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Mesenteric Artery Preservation
Description: Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Mesenteric Artery Ligation
Description: Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
Study: NCT03062904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Bronchodilators +/- Inhaled Methacholine
Description: 1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations
Study: NCT04436627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-1
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
Study: NCT04436627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-2
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-3
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
Study: NCT01892033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12 weeks of brisk walking
Study: NCT03862079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam
Description: Given PO
Study: NCT02351245

Intervention type: OTHER
Intervention: observation
Study: NCT00736710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
Study: NCT04238637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous Infusion)
Study: NCT02965872

Intervention type: OTHER
Intervention: No intervention
Study: NCT02752802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Coronary Angiogram
Description: Diagnostic angiographic procedure with the use of the DyeVert System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Coronary Angiogram
Description: Diagnostic angiographic procedure with the use of the DyeVert System.
Study: NCT02622659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuganlin Oral Liquid
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Study: NCT04200963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175
Description: Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175
Description: Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175 and nivolumab
Description: Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175 and nivolumab
Description: Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
Study: NCT00789711

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines

Intervention type: DRUG
Intervention: insulin detemir
Description: Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
Study: NCT02615288

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Study: NCT04032548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study: NCT02615288

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Study: NCT03130049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal plexus block
Description: 10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
Study: NCT03606642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet (DAPT) Therapy
Description: DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Synergy® stent
Description: IVUS guided stent
Study: NCT02727842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP950 Sound Processor
Description: An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless programming pod
Description: The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
Study: NCT03781427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Description: Left ventricular pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy
Description: Left ventricular pacing
Study: NCT00645749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Helminth ova
Description: 2500 ova per dose (liquid form)
Study: NCT00375037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT02051231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L
Study: NCT01536470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noradrenaline
Description: The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ephedryne chorydrate
Study: NCT02645097

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous Nerve Block
Description: A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous Nerve Block
Description: A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
Study: NCT01050283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: [18F]-FDG PET/CT and Volumetric CT
Description: Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
Study: NCT01874600

Intervention type: DEVICE
Intervention: Brain Sentinel Seizure Detection Device and Warning System
Description: The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
Study: NCT03730675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal irradiation stent placement
Description: The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
Study: NCT02494674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter tracking
Description: Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
Study: NCT00741728

Intervention type: OTHER
Intervention: Spider flash EKG, echocardiography tracking, step test
Description: cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
Study: NCT01172262

Intervention type: PROCEDURE
Intervention: MRI
Description: This is an observational study, no intervention will occur.
Study: NCT02499926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT03881475

Intervention type: OTHER
Intervention: questionnaire
Description: During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes.
Study: NCT03985059

Intervention type: OTHER
Intervention: Transcranial Doppler
Description: Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet.

Intervention type: OTHER
Intervention: Transcranial Doppler
Description: Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet.
Study: NCT04746898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Students received their basic life support application training through virtual reality glasses with special software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation Training
Description: Students received their basic life support application training through high fidelity simulator mannequins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fidelity Simulation Training
Description: Students received their basic life support application training through low fidelity simulator mannequins.
Study: NCT06565351

Intervention type: OTHER
Intervention: eGFR estimated from creatinine and cystatin C
Description: eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
Study: NCT04053322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
Study: NCT06322069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention group
Description: Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
Study: NCT01210469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening and balance exercises
Description: The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and balance exercises
Description: The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
Study: NCT03000569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiparkinsonian Agent(s)
Description: Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.